NMTC
NeuroOne Medical Technologies Corporation
NMTC lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
NMTC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
NMTC's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NMTC PE Valuation
NMTC has no meaningful PE right now: it lost money over the past year.
NMTC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect NMTC's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NMTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.04 | -$0.14 |
| Q1 2026 | -$0.94 | +$0.38 |
| Q4 2025 | -$1.08 | +$0.48 |
| Q3 2025 | -$0.54 | +$2.22 |
| Q2 2025 | -$0.90 | +$1.98 |
| Q1 2025 | -$1.32 | +$2.16 |
| Q4 2024 | -$1.56 | +$2.52 |
| Q3 2024 | -$2.76 | +$1.14 |
NMTC is still losing money, but far less than before: $1.04 per share over the past year, against $17.46 at its worst in mid-2020.
NMTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2M | +16% |
| Q1 2026 | $1.9M | +34% |
| Q4 2025 | $2.9M | -12% |
| Q3 2025 | $2.7M | +907% |
| Q2 2025 | $1.7M | +105% |
| Q1 2025 | $1.4M | +0.7% |
| Q4 2024 | $3.3M | +235% |
| Q3 2024 | $272.3K | -63% |
NMTC's revenue is recovering but still below its 2024 peak: $2M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -123% | -12 points |
| Q1 2026 | -129% | +65 points |
| Q4 2025 | -59% | -111 points |
| Q3 2025 | -50% | +985 points |
| Q2 2025 | -111% | +227 points |
| Q1 2025 | -193% | +16 points |
| Q4 2024 | 52% | +399 points |
| Q3 2024 | -1034% | -608 points |
NMTC's operating margin was −123% last quarter, down 12 points from the same quarter a year ago.
NMTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$1.4M | -$1.3M |
| Q4 2025 | -$3.2M | -1617% |
| Q3 2025 | -$1.5M | +$1.2M |
| Q1 2025 | -$56.1K | +$2.2M |
| Q4 2024 | $208K | +$4.1M |
| Q3 2024 | -$2.7M | +$256.7K |
| Q2 2024 | -$2.4M | +$704.3K |
| Q1 2024 | -$2.2M | +$1.5M |
NMTC has burned cash in almost every quarter: −$7M over the past year, against −$5M the year before.
NMTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +255K shares |
| 1 year | +69% | +3.6M shares |
| 3 years | +223% | +6M shares |
| 5 years | +868% | +7.8M shares |
| Available history | +1227% | +8.1M shares |
NMTC has 9M diluted shares, up 69% from a year ago.
NMTC Net Leverage
NMTC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NMTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.9 | Oversold |
| Stochastic | 3.3 | Oversold |
NMTC's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
NMTC PE vs Healthcare Sector
NMTC has no meaningful PE right now: it lost money over the past year.
NMTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.00 | 25% below |
| 20 week MA | $1.59 | 53% below |
| 50 week MA | $3.28 | 77% below |
| 100 week MA | $4.09 | 82% below |
| 200 week MA | $5.51 | 86% below |
NMTC is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
NMTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.7 | $27.5 | -32% |
| 2021 | $27.5 | $13.2 | -52% |
| 2022 | $13.2 | $9.24 | -30% |
| 2023 | $9.24 | $9.48 | +2.6% |
| 2024 | $9.48 | $4.91 | -48% |
| 2025 | $4.91 | $4.38 | -11% |
| 2026 YTD | $4.38 | $0.75 | -83% |
NMTC has finished lower in five of the last six years. It's down 83% so far in 2026.